Look in the MiR: MicroRNA Fans Neurogenesis in Old Alzheimer’s Mice
Overexpressing miR-132 dampened AD pathology in young mice, and appeared to nourish the birth of new hippocampal neurons in older animals.
ALL NEWS
6545 RESULTS
Sort By:
- Most Recent
- Most Commented
Cognitive Aging Summit III
NIH Summit Examines What Makes a Healthy Aging Brain
Transcranial Magnetic Stimulation for AD Boasts Success in Phase 3
Manufacturers of a therapy system called neuroAD, which combines transcranial magnetic stimulation with cognitive training, are applying for FDA marketing clearance.
Treating Tau: Finally, Clinical Candidates Are Stepping into the Ring
Three anti-tau antibodies are in Phase 1 or 2, while an O-GlcNAcase inhibitor got the green light to start testing.
Two For One? ASOs for Ataxin Allay ALS and SCA2 in Mice
Using torpedo-like DNA snippets to delete mRNAs from cells, scientists lowered the amount of ataxin-2 protein. This allayed disease in mouse models of two neurodegenerative disorders.
NIH, Alzheimer’s Research Get Congressional Thumbs Up
Congress has opposed the Trump administration’s request to cut NIH funding, agreeing on a $2 billion boost, with a $400 million bonus for Alzheimer’s research.
Inside Out, or Outside In? ALS Turns on Monocytes in Blood
People with ALS—especially those who progress fast—express myriad inflammatory genes in their blood monocytes.
Potential New ALS Gene Leads to Extraordinary Aggregates
Found in familial and sporadic cases of ALS, mutations in the annexin A11 gene lead to elaborate protein clumps and seem to disrupt vesicular trafficking.
Do Smartphones Collect Better Clinical Data Than Paper-and-Pencil Tests?
A trial of an α-synuclein antibody is making use of the technology to follow subtle changes in the day-to-day function of participants.
α-Synuclein Antibodies Enter Phase 2, Sans Biomarker
Even without this important sidekick at hand, scientists are forging ahead with efficacy trials of their first attempts at disease-modification in Parkinson’s
FDA Approves Edaravone for Treatment of ALS
The drug slows functional decline in patients with mild disease and should be available to U.S. patients in August.
Non-Amyloid Treatments: Inflammation, Epigenetics, Regeneration
A broadening drug development pipeline now contains Phase 1 or 2 drugs on targets unrelated to Aβ or tau.
Olfactory System Model Explores Antimicrobial Role for α-Synuclein
Preparing the whole mouse head—not just the dissected brain—lets researchers analyze the neural tissue outside the skull that connects the nose to the inner sanctum.
Anti-Amyloid Drug Pipeline Shows No Sign of Drying Up
Researchers at AD/PD 2017 presented new data on an antibody and small molecules targeting amyloid.
What Price Success? Ionis Drug Worked in Phase 3 but Had Serious Side Effects
Ionis announced top-line results of a Phase 3 trial of their drug for familial amyloid neuropathy. It met both primary endpoints but caused serious side effects in some people.
Current Filters
No filters selected